Split History
ETFs Holding CAPR »    CAPR Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Capricor Therapeutics is a clinical-stage biotechnology company. Co.'s drug candidates include: CAP-1002, which consists of allogeneic cardiosphere-derived cells; Cenderitide (CD-NP), which belongs to a class of drugs called natriuretic peptides that provide a therapeutic option for the outpatient treatment of heart failure; Exosomes, which are nano-sized, membrane-enclosed vesicles, or bubbles, that are filled with select molecules, which, when released, send messages to neighboring cells to regulate cellular functions; CAP-1001, which consists of autologous CDCs; CU-NP, which is a pre-clinical rationally-designed natriuretic peptide; and CSps, which are multicellular clusters. According to our CAPR split history records, Capricor Therapeutics has had 1 split.
CAPR split history picture
Capricor Therapeutics (CAPR) has 1 split in our CAPR split history database. The split for CAPR took place on November 12, 1997. This was a 1 for 10 reverse split, meaning for each 10 shares of CAPR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as Capricor Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the CAPR split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Capricor Therapeutics shares, starting with a $10,000 purchase of CAPR, presented on a split-history-adjusted basis factoring in the complete CAPR split history. CAPR split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/24/2007
End date: 04/21/2017
Start price/share: $2.00
End price/share: $3.01
Dividends collected/share: $0.00
Total return: 50.50%
Average Annual Total Return: 4.17%
Starting investment: $10,000.00
Ending investment: $15,046.19
Years: 10.00
Date Ratio
11/12/19971 for 10
CAPR is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CASC Split History
CBIO Split History
CBLI Split History
CBM Split History
CBMX Split History
CBRX Split History
CCM Split History
CDXC Split History
CELG Split History
CERE Split History

Rexahn Pharmaceuticals, Inc. (RNN)
Immune Pharmaceuticals Inc. (INMP)
DryShips Inc. (DRYS)
STRATA Skin Sciences, Inc. (SSKN)
Quantum Corp. (QTM)
German American Bancorp, Inc. (GABC)
Pacific Energy Development (PED)
The GEO Group, Inc. (GEO)
Copart, Inc. (CPRT)
HEICO Corporation (HEI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CAPR Insider Buying

CAPR Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.